Genetics of Heritable Thoracic Aortic Disease: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Vivi Li and Version 1 by Efstathios C Papatheodorou.

Genetic testing plays an increasing diagnostic and prognostic role in the management of patients with heritable thoracic aortic disease (HTAD). The identification of a specific variant can establish or confirm the diagnosis of syndromic HTAD, dictate extensive evaluation of the arterial tree in HTAD with known distal vasculature involvement and justify closer follow-up and earlier surgical intervention in HTAD with high risk of dissection of minimal or normal aortic size. Evolving phenotype–genotype correlations lead us towards more precise and individualized management and treatment of patients with HTAD. 

  • aortopathy
  • bicuspid aortic valve
  • familial thoracic aneurysm
  • Marfan syndrome
  • Loeys–Dietz syndrome
  • aortic dissection
  • heritable thoracic aortic disease

1. Introduction

Over the last two decades, genetic developments have significantly improved our understanding of heritable thoracic aortic disease (HTAD). The identification of new syndromes [1] and novel candidate genes [2] has changed the paradigm in the diagnostic evaluation of these patients. Specific genotype–phenotype correlations continue to emerge, promising a more precise and effective approach in the treatment of HTAD [3,4,5][3][4][5]. The goal of this review is to inform clinicians about the value and effect of genetics in the diagnosis, management, surveillance, risk stratification and familial evaluation of patients with HTAD. 

1.1. Classification

The presence of syndromic systemic features and a positive family history of aortic aneurysm or dissection are the key elements that determine the classification and thus the management of patients with HTAD. Thoracic aortic disease at a younger age occurs more often in the context of a genetic syndrome.
Syndromic HTAD (sHTAD) typically exhibits a multiorgan phenotype and is caused by genetic variants that are involved in the transforming growth factor-β (TGF-β) pathway and genes encoding extracellular matrix proteins [2]. Nonsyndromic HTAD (nsHTAD) is typically characterized by isolated thoracic aortic aneurysm or dissection, without any recognizable systemic features, and can be familial in up to 20–25% of cases. A genetic defect, mainly in genes of the contractile apparatus, may be identified in up to 20% of familial nsHTAD [6].

1.2. Diagnostic Workup

Only 5% of patients present with alarming symptoms before an acute aortic event [7]. Most patients are usually diagnosed following a major complication, e.g., an aortic dissection, as part of familial evaluation, or based on characteristic physical findings suggestive of a specific syndrome.
Physical examination and history are vital in the assessment of patients with HTAD. The physician should be able to recognize any systemic features such as specific facial characteristics, skin lesions or skeletal manifestations, which suggest the presence of sHTAD. A detailed personal history should be obtained including history of recurrent pneumothorax, history of eye operations or ocular conditions. Ophthalmology evaluation, including slit-lamp examination, should be offered in all patients with a suspicion of Marfan syndrome (MFS). The reduced penetrance or incomplete expression and the phenotypic overlap and variability of hereditary aortopathy consist of major challenges, which make essential a multidisciplinary diagnostic approach.

2. Syndromic HTAD

2.1. Marfan Syndrome

Marfan syndrome (MFS; Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USA OMIM #154700, Orphanet rare disease nomenclature, French National Institute for Health and Medical Research, Paris, France ORPHA:558) is the most common syndromic aortopathy. It is characterized by aortic dilatation, ectopia lentis and skeletal abnormalities. MFS is associated with variants in the FBN1 gene, encoding the extracellular matrix protein called fibrillin-1 [8]. Other genes, typically not causing any ocular involvement, also can lead to a phenotype resembling MFS [2].
The diagnosis of MFS is based on the revised 2010 Ghent criteria [8]. A pathogenic FBN1 variant, along with ectopia lentis or enlarged aortic root (Z score ≥2 that corresponds to a diameter ≥2 standard deviations above normal, according to established aortic nomograms [9]), establishes the diagnosis. In the absence of a pathogenic FBN1 variant, the diagnosis can be made in patients with aortic dilatation (Z score ≥2) and ectopia lentis or a systemic score ≥7 (encompassing systemic features suggestive of MFS) [8]. In patients with a family history of MFS, the diagnosis can be made in the presence of ≥1 of the following criteria: (a) ectopia lentis, (b) systemic score ≥7, (c) aortic root enlargement with Z-score ≥2 in patients >20 years and (d) Z score ≥3 in patients <20 years [8].
Over half of MFS patients are diagnosed after adolescence (median age of diagnosis is 19 years) [10], and the first cardiovascular procedure occurs at average at the age of 36 years [11]. Aortic dilatation typically occurs at the level of the sinuses of Valsalva (SoV), but aortic dilatation or dissection can occur at every level of the aorta [12]. Most patients with MFS are diagnosed before severe cardiac complications occur. This is particularly relevant, as MFS patients appear to have better survival rates with appropriate medical management and when undergoing prophylactic elective surgery (complication rate of 1.5% vs. 11.7% of urgent procedures) [13]. Established clinical factors of high risk are: (a) aortic diameter at the SoV ≥5 cm, (b) rapid increase in aortic dilatation (≥3 mm per year), (c) family history of aortic dissection at a low aortic size, (d) progressive aortic regurgitation, (e) personal history of spontaneous vascular dissection and (f) desire for pregnancy [14,15][14][15]. Therapy is based on optimal blood pressure control, and medical management includes beta-blockers or angiotensin-1 antagonists (losartan) [14,16,17][14][16][17].
Most FBN1 variants are missense, having in most cases a dominant-negative effect (DN-FBN1), resulting in a disorganized extracellular matrix incorporating both mutated and nonmutated fibrillin-1 proteins. Haploinsufficient FBN1 variants (HI-FBN1), leading to reduced production of normal fibrillin-1 protein, are also well documented in up to 35% of MFS patients [5]. It has been reported that patients with HI-FBN1 are at increased risk of aortic dissection and death, have more rapid aortic root and ascending aorta dilation rates, manifest more severe cardiovascular complications and respond better to losartan therapy than patients with DN-FBN1 variants [5,18,19,20,21][5][18][19][20][21]. In a large cohort of MFS patients, premature termination codon variants leading to haploinsufficiency were associated with an 83% lifelong aortic event risk during life, shorter life expectancy, severe scoliosis and relatively lower rates of ectopia lentis surgery [22].
Specific DN-FBN1 variants have been linked with a similarly severe phenotype compared to HI-FBN1 variants. MFS patients with in-frame DN-FBN1 variants leading to a cysteine loss at the level of fibrillin-1 showed 73% lifelong risk of aortic dissection or surgery, high rates of severe scoliosis and ectopia lentis surgery. In-frame variants leading to a neutral cysteine effect were associated with an intermediate phenotype (61% of lifelong aortic event risk). In-frame variants leading to cysteine gain were associated with a better cardiovascular profile (29% of lifelong aortic event risk) and lower rates of severe scoliosis but high risk for ectopia lentis surgery [22]. Takeda et al. identified deleterious high-risk variants among DN-FBN1 Japanese patients, in-specific variants affecting or creating cysteine residues and in-frame deletion variants in exons 25–36 and 43–49 [19].
Furthermore, despite a greater frequency of surgery and type B aortic dissections in MFS patients harboring HI-FBN1 variants, all type A dissections that occurred at an aortic root diameter <50 mm were DN-FBN1 variants in a cohort of 954 MFS patients followed for a mean 9.1 years [23].

2.2. Loeys–Dietz Syndrome

Loeys–Dietz syndrome (LDS, ORPHA:60030) is characterized by the combination of arterial tortuosity with ascending aortic aneurysm/dissection, also involving the distal aorta and branching arteries, hypertelorism and bifid uvula or cleft palate. It was first described in 2005 as a novel autosomal dominant syndromic aortopathy [1]. Since 2005, loss-of-function variants in six genes have been linked to LDS (TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2 and TGFB3), all of which are involved in the TGF-β signaling pathway [4].
LDS has been originally associated with a very aggressive natural history, probably reflecting a selection bias in the first series of patients. Aortic dissection in young patients (mean age at death of 26 years), very high incidence of pregnancy-related complications and aortic dissections at only mildly increased or even much normal aortic dimensions have been reported [1]. Current American Heart Association/American College of Cardiology guidelines suggest an aggressive approach with prophylactic surgery in aortic size ≥42 mm in all patients with LDS [24]. Recent European Society of Cardiology (ESC) guidelines suggest surgery in patients with TGFBR1 or TGFBR2 pathogenic variants with maximal aortic sinus diameter ≥45 mm [15]. Although there is no scientific evidence published to date, drug treatment with beta-blockers and/or angiotensin blockade and optimal antihypertensive management is thought to improve prognosis in LDS patients in a similar fashion to MFS patients. Extensive and distal vascular involvement in LDS patients warrants regular and more extensive imaging of the arterial tree (from head to pelvis).

2.3. Rare Syndromic HTAD

2.3.1. Vascular Ehlers–Danlos Syndrome (vEDS; OMIM #130050)

It is a rare autosomal dominant syndromic HTAD caused by genetic defects in the COL3A1 gene. Rarely, vEDS can be caused by specific arginine-to-cysteine substitution variants in the COL1A1 gene. The syndrome is characterized by arterial, uterine or bowel ruptures, skin translucency with visible veins and easy bruising and characteristic facial features (thin pinched nose, prominent eyes and lobeless ears, lack of subcutaneous fat). Diagnosis is established using the 2017 International Classification of the Ehlers–Danlos syndrome [31][25], which updated the earlier nosology of Villefranche [32][26]. Men seem to have a poorer prognosis than women (median survival age of 46 ± 1.8 years vs. 54 ± 2.5 years) [33][27]. Surveillance may include periodic arterial screening.
Genetic testing is highly specific and sensitive for vEDS, revealing a genetic defect in 95% of cases [34][28]. Lethal arterial events in classic (nonvascular) Ehlers–Danlos syndrome (EDS) caused by COL5A1 or COL1A1 variants have also been reported [35][29]. Identification of a pathogenic variant establishes the diagnosis [32][26]. The clinical phenotype and prognosis of vEDS may be influenced by the type of COL3A1 variant. Patients heterozygous for “null” COL3A1 variants, leading to loss of the stable mRNA from one COL3A1 allele, show late-onset disease, reduced penetrance, solely vascular events and longest survival compared to missense and splicing variants [33,36,37,38][27][30][31][32]. Glycine substitutions, splice-site and in-frame insertions/deletions bear the poorer prognosis leading to earlier complications [39][33].
Although aortic dissection can occur at normal aortic sizes in up to 33% of patients [40][34], aortic surgery is not usually recommended due to the high rate of intraoperative mortality caused by extreme fragility of the vessel walls. Surgery is usually performed urgently to treat potentially life-threatening complications. Endovascular repair with coil embolization has shown promising results in selected cases of ruptured pseudoaneurysms, visceral aneurysms and carotid-cavernous fistulas. A multicenter, randomized and blinded open trial study showed significantly lower arterial events (rupture or dissection) in vEDS patients receiving celiprolol, a β(1)-adrenoceptor antagonist with a β(2)-adrenoceptor agonist action, compared to controls [41][35]. Encouraging reports from animal models and an observational study in favor of celiprolol have been published since; however, no randomized prospective trials exist to date [38,42][32][36].

2.3.2. Meester–Loeys Syndrome (MRLS; OMIM #300989)

Loss-of-function variants in the X-linked biglycan gene (BGN) have been described in five families with syndromic features overlapping with those of LDS and MFS patients. It is characterized by early-onset aneurysms of the aortic root or ascending aorta (as early as age 1) and aortic dissection (earliest at the age of 15 at an aortic size of 45 mm at the SoV) in male probands. Distal aneurysms in the brain have been detected in one patient. Female patients showed a relatively milder phenotype [43][37].

2.3.3. Filamin A-Related HTAD

Pathogenic variants in the X-linked filamin A (FLNA) gene, encoding an actin-binding protein that regulates the cytoskeleton and cell motility, cause the brain malformation periventricular heterotopia (PVNH; OMIM #300049, ORPHA:82004), which may also occur in association with EDS features [44][38]. Neurological symptoms include mainly seizures and dyslexia. Chen et al. reported on the largest series to date of 114 patients, with loss-of-function FLNA pathogenic variants and found aortic dilatation in 18.4% of the patients [45][39]. Aortic rupture occurred in a 41-year-old male patient at an aortic root size of 42 mm. Pulmonary artery dilatation and aneurysms of other vessels (in the subclavian, middle cerebral and internal carotid arteries, as well as in the abdominal aorta) were common.

2.3.4. LOX-Related HTAD

Loss-of-function variants in the LOX gene, encoding a lysyl oxidase involved in the remodeling of the extracellular matrix, have been shown to predispose to aortic root and fusiform aneurysms, involving both the aortic root and ascending aorta [46,47][40][41]. These patients exhibit some overlapping syndromic MFS features, without, however, fulfilling the Ghent criteria. No cases of aortic dissection in minimal aortic dimensions have been reported to date. Presence of a bicuspid aortic valve (BAV) has been found in up to 15% of LOX carriers [46][40].

3. Nonsyndromic HTAD

3.1. Bicuspid Aortic Valve Related HTAD

Bicuspid aortic valve (BAV; OMIM #109730, ORPHA:402075) is the most common congenital heart disease with an estimated prevalence of 0.5–0.8% [81][42]. Although BAV can be part of the phenotype in some cases of sHTAD such as MFS or LDS [82][43], there is also mounting evidence of familial clustering in up to 6–9% of first-degree relatives of nonsyndromic BAV [83,84][44][45]. An autosomal dominant inheritance pattern with variable expressivity and typically incomplete penetrance is recognized [82,84][43][45]. Up to 75% of patients with BAV might develop aortic dilatation [85][46], although this typically occurs later than other syndromic or nonsyndromic HTAD and at relatively slower growth rates (average of 0.19 cm/year) [86][47].
Variants in the NOTCH1 gene have been described in approximately 1% of sporadic BAV cases and in up to 7% of familial BAV cases [82,87,88][43][48][49] and are typically associated with prominent valve calcification [89][50]. Recently, loss-of-function SMAD6 variants have been found in up to 11% of nsHTAD patients with BAV [90,91][51][52]. ROBO4 variants, encoding a factor known to contribute to endothelial performance, and TBX20 variants, a transcription factor involved in the regulation of heart development, were shown to contribute to aortic aneurysm formation in families with nonsyndromic BAV [92,93][53][54].
Echocardiography screening of first-degree relatives of patients with BAV should be offered especially in boys, athletes and if hypertension is present [24]. Families with multiple affected relatives, a combination of other left-sided congenital abnormalities and a particularly malignant clinical profile should be offered genetic testing for at least ACTA2, SMAD6, TBX20, ROBO4 and NOTCH1 genes. Multiple gene panels should be considered in selected cases, taking into consideration the variable and incomplete penetrance of sHTAD that might lead to a mild phenotype with minimal or no systemic features in some patients. No specific genotype–phenotype correlations currently exist that could possibly guide surgical interventions or provide specific prognostic information. Recently, Pileggi et al. indicated that specific NOTCH1 variants could be associated with better prognosis and later-onset development of aortic stenosis [88][49].

3.2. Familial and Sporadic Nonsyndromic HTAD

Based on the presence of familial disease or not, nsHTAD is further categorized into familial and sporadic nsHTAD. A positive family history of thoracic aortic disease is associated with an increased aortic growth rate, a bigger chance of gene identification and earlier phenotypic manifestation [94][55]. The genetic etiology of familial nsHTAD is highly heterogeneous and usually involves genes that regulate the smooth muscle cell contractile apparatus. The genetic substrate of sporadic nsHTAD is largely unknown and seems to differ from familial nsHTAD cases.
To date, over 10 genes and 2 linked loci have been involved in the pathogenesis of nsHTAD, including genes involved in the (TGF-β) pathway and genes encoding extracellular matrix proteins that are typically associated with syndromic aortopathies [2,6,47][2][6][41]. Common single nucleotide polymorphisms at the 15q21.1 locus of the FBN1 gene have been shown to be associated with sporadic nsHTAD [95][56] without other systemic features of MFS. Arnaud et al. performed genetic screening in 226 consecutive nsHTAD, either sporadic in patients under 45 years of age or in documented familial cases, and identified an overall yield of pathogenic or likely pathogenic variants (SMAD3, FBN1, TGFBR1, TGFBR2, TGFB2, ACTA2, MYLK, FLNA, FBN2, LOX, MFAP5 genes) in 18% of the patients (11% in sporadic cases vs. 22% in familial cases), with almost two-thirds located in SMAD3 and FBN1 genes. Exclusively missense variants and no premature termination codon variants were identified in the FBN1 gene in this cohort. More careful clinical evaluation after the genetic result revealed clinical findings consistent with LDS in approximately half of the cases with SMAD3 variants and history of periventricular heterotopia in patients with the FLNA variant, reclassifying these cases as syndromic [6]. Weerakkody et al. investigated a cohort of 1025 unrelated HTAD cases, including many cases of sporadic HTAD, and reported a 4.9% yield of genetic testing for a 15-gene genetic panel. Patients with a family history of HTAD were four times more likely to carry a pathogenic or likely pathogenic variant than those without a family history (9.8 vs. 2.4%) [96][57]. Since clinical information (syndromic features or clinical diagnosis) was not available in a significant percentage of the cases, these cases cannot automatically be categorized as sporadic nsHTAD.
Overall, pathogenic ACTA2 variants are the most frequently encountered, as they are detected in 1–21% of nsHTAD [57,97,98][58][59][60] and are associated with a malignant aortic phenotype. Pathogenic variants in the MYLK gene [99[61][62][63],100,101], with missense pathogenic variants showing an earlier onset aortic event, and variants in the MYH11 [102][64] and PRKG1 genes [103][65] have also been recognized as relatively rare but aggressive causes of thoracic aortic dissection (~1% prevalence of each), in nsHTAD which are not always preceded by obvious aortic dilatation. There is no evidence to date that defects in the other genes identified (LOX, MFAP5, FOXE3, MAT2A, SMAD2, SMAD4, NOTCH1, PLOD1, TGFB2, TGFBR2, FBN1, FBN2) are linked to a more severe phenotype or earlier presentation of HTAD [6,57,58][6][58][66].

References

  1. Loeys, B.L.; Schwarze, U.; Holm, T.; Callewaert, B.L.; Thomas, G.H.; Pannu, H.; De Backer, J.F.; Oswald, G.L.; Symoens, S.; Manouvrier, S.; et al. Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor. N. Engl. J. Med. 2006, 355, 788–798.
  2. Verstraeten, A.; Luyckx, I.; Loeys, B. Aetiology and management of hereditary aortopathy. Nat. Rev. Cardiol. 2017, 14, 197–208.
  3. Hostetler, E.M.; Regalado, E.S.; Guo, D.-C.; Hanna, N.; Arnaud, P.; Muiño-Mosquera, L.; Callewaert, B.L.; Lee, K.; Leal, S.M.; Wallace, S.E.; et al. SMAD3 pathogenic variants: Risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium. J. Med. Genet. 2019, 56, 252–260.
  4. Jondeau, G.; Ropers, J.; Regalado, E.; Braverman, A.; Evangelista, A.; Teixedo, G.; De Backer, J.; Muiño-Mosquera, L.; Naudion, S.; Zordan, C.; et al. International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations. Circ. Cardiovasc. Genet. 2016, 9, 548–558.
  5. Franken, R.; Teixido-Tura, G.; Brion, M.; Forteza, A.; Palomares, J.F.R.; Gutierrez, L.; Dorado, D.G.; Pals, G.; Mulder, B.J.; Evangelista, A. Relationship between fibrillin-1 genotype and severity of cardiovascular involvement in Marfan syndrome. Heart 2017, 103, 1795–1799.
  6. Arnaud, P.; Hanna, N.; Benarroch, L.; Aubart, M.; Bal, L.; Bouvagnet, P.; Busa, T.; Dulac, Y.; Dupuis-Girod, S.; Edouard, T.; et al. Genetic diversity and pathogenic variants as possible predictors of severity in a French sample of nonsyndromic heritable thoracic aortic aneurysms and dissections (nshTAAD). Genet. Med. 2019, 21, 2015–2024.
  7. Elefteriades, J.A.; Farkas, E.A. Thoracic Aortic Aneurysm. Clinically Pertinent Controversies and Uncertainties. J. Am. Coll. Cardiol. 2010, 55, 841–857.
  8. Loeys, B.L.; Dietz, H.C.; Braverman, A.C.; Callewaert, B.L.; De Backer, J.; Devereux, R.B.; Hilhorst-Hofstee, Y.; Jondeau, G.; Faivre, L.; Milewicz, D.M.; et al. The revised Ghent nosology for the Marfan syndrome. J. Med. Genet. 2010, 47, 476–485.
  9. Devereux, R.B.; De Simone, G.; Arnett, D.K.; Best, L.G.; Boerwinkle, E.; Howard, B.V.; Kitzman, D.; Lee, E.T.; Mosley, T.H. Weder, A. et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥ 15 years of age. Am. J. Cardiol. 2012, 110, 1189–1194.
  10. Groth, K.A.; Hove, H.; Kyhl, K.; Folkestad, L.; Gaustadnes, M.; Vejlstrup, N.; Stochholm, K.; Østergaard, J.R.; Andersen, N.H.; Gravholt, C.H. Prevalence, incidence, and age at diagnosis in Marfan Syndrome. Orphanet J. Rare Dis. 2015, 10, 153.
  11. Treasure, T.; Takkenberg, J.J.M.; Pepper, J. Surgical management of aortic root disease in Marfan syndrome and other congenital disorders associated with aortic root aneurysms. Heart 2014, 100, 1571–1576.
  12. De Beaufort, H.W.L.; Trimarchi, S.; Korach, A.; Di Eusanio, M.; Gilon, D.; Montgomery, D.G.; Evangelista, A.; Braverman, A.C.; Chen, E.P.; Isselbacher, E.M.; et al. Aortic dissection in patients with Marfan syndrome based on the IRAD data. Ann. Cardiothorac. Surg. 2017, 6, 633–641.
  13. Gott, V.L.; Greene, P.S.; Alejo, D.E.; Cameron, D.E.; Naftel, D.C.; Miller, D.C.; Gillinov, A.M.; Laschinger, J.C.; Pyeritz, R.E.; Borst, H.G.; et al. Replacement of the aortic root in patients with Marfan’s syndrome. N. Engl. J. Med. 1999, 340, 1307–1313.
  14. Erbel, R.; Aboyans, V.; Boileau, C.; Bossone, E.; Di Bartolomeo, R.; Eggebrecht, H.; Evangelista, A.; Falk, V.; Frank, H.; Gaemperli, O.; et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases. Eur. Heart J. 2014, 35, 2873–2926.
  15. Baumgartner, H.; De Backer, J.; Babu-Narayan, S.V.; Budts, W.; Chessa, M.; Diller, G.-P.; Lung, B.; Kluin, J.; Lang, I.M.; Meijboom, F.; et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur. Heart J. 2020, 42, 563–645.
  16. Suzuki, T.; Isselbacher, E.M.; Nienaber, C.A.; Pyeritz, R.E.; Eagle, K.A.; Tsai, T.T.; Cooper, J.V.; Januzzi, J.L.; Braverman, A.C.; Montgomery, D.G.; et al. Type-selective benefits of medications in treatment of acute aortic dissection (from the International Registry of Acute Aortic Dissection ). Am. J. Cardiol. 2012, 109, 122–127.
  17. Update on Clinical Trials of Losartan with and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review. JAMA Cardiol. 2019, 4, 702–707.
  18. Franken, R.; den Hartog, A.W.; Radonic, T.; Micha, D.; Maugeri, A.; van Dijk, F.S.; Meijers-Heijboer, H.E.; Timmermans, J.; Scholte, A.J.; van den Berg, M.P.; et al. Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. Circ. Cardiovasc. Genet. 2015, 8, 383–388.
  19. Takeda, N.; Inuzuka, R.; Maemura, S.; Morita, H.; Nawata, K.; Fujita, D.; Taniguchi, Y.; Yamauchi, H.; Yagi, H.; Kato, M.; et al. Impact of Pathogenic FBN1 Variant Types on the Progression of Aortic Disease in Patients With Marfan Syndrome. Circ. Genom. Precis. Med. 2018, 11, e002058.
  20. De Backer, J.; Campens, L.; Muiño Mosquera, L. Looking for the Missing Links: Challenges in the Search for Genotype-Phenotype Correlation in Marfan Syndrome. Circ. Genom. Precis. Med. 2018, 11, e002185.
  21. Baudhuin, L.M.; Kotzer, K.E.; Lagerstedt, S.A. Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events. Genet. Med. 2015, 17, 177–187.
  22. Arnaud, P.; Milleron, O.; Hanna, N.; Ropers, J.; Ould Ouali, N.; Affoune, A.; Langeois, M.; Eliahou, L.; Arnoult, F.; Renard, P.; et al. Clinical relevance of genotype–phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet. Med. 2021, 23, 1296.
  23. Milleron, O.; Arnoult, F.; Delorme, G.; Detaint, D.; Pellenc, Q.; Raffoul, R.; Tchitchinadze, M.; Langeois, M.; Guien, C.; Beroud, C.; et al. Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome. J. Am. Coll. Cardiol. 2020, 75, 843–853.
  24. Hiratzka, L.F.; Bakris, G.L.; Beckman, J.A.; Bersin, R.M.; Carr, V.F.; Casey, D.E.; Eagle, K.A.; Hermann, L.K.; Isselbacher, E.M.; Kazerooni, E.A.; et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines, American association for thoracic surgery, American college of radiology, American stroke association. Circulation 2010, 121, 1544–1579.
  25. Malfait, F.; Francomano, C.; Byers, P.; Belmont, J.; Berglund, B.; Black, J.; Bloom, L.; Bowen, J.M.; Brady, A.F.; Burrows, N.P.; et al. The 2017 international classification of the Ehlers-Danlos syndromes; The 2017 international classification of the Ehlers-Danlos syndromes. Am. J. Med. Genet. Part C Semin. Med. Genet. 2017, 175, 8–26.
  26. Beighton, P.; De Paepe, A.; Steinmann, B.; Tsipouras, P.; Wenstrup, R.J. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am. J. Med. Genet. 1998, 77, 31–37.
  27. Pepin, M.; Schwarze, U.; Superti-Furga, A.; Byers, P.H. Clinical and Genetic Features of Ehlers–Danlos Syndrome Type IV, the Vascular Type. N. Engl. J. Med. 2000, 342, 673–680.
  28. Schwarze, U.; Schievink, W.I.; Petty, E.; Jaff, M.R.; Babovic-Vuksanovic, D.; Cherry, K.J.; Pepin, M.; Byers, P.H. Haploinsufficiency for One COL3A1 Allele of Type III Procollagen Results in a Phenotype Similar to the Vascular Form of Ehlers-Danlos Syndrome, Ehlers-Danlos Syndrome Type IV. Am. J. Hum. Genet. 2001, 69, 989–1001.
  29. Monroe, G.R.; Harakalova, M.; van der Crabben, S.N.; Majoor-Krakauer, D.; Bertoli-Avella, A.M.; Moll, F.L.; Oranen, B.I.; Dooijes, D.; Vink, A.; Knoers, N.V.; et al. Familial Ehlers-Danlos syndrome with lethal arterial events caused by a mutation in COL5A1. Am. J. Med. Genet. Part A 2015, 167, 1196–1203.
  30. Leistritz, D.F.; Pepin, M.G.; Schwarze, U.; Byers, P.H. COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet. Med. 2011, 13, 717–722.
  31. Pepin, M.G.; Schwarze, U.; Rice, K.M.; Liu, M.; Leistritz, D.; Byers, P.H. Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV). Genet. Med. 2014, 16, 881–888.
  32. Frank, M.; Adham, S.; Seigle, S.; Legrand, A.; Mirault, T.; Henneton, P.; Albuisson, J.; Denarié, N.; Mazzella, J.M.; Mousseaux, E.; et al. Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study. J. Am. Coll. Cardiol. 2019, 73, 1948–1957.
  33. Frank, M.; Albuisson, J.; Ranque, B.; Golmard, L.; Mazzella, J.-M.; Bal-Theoleyre, L.; Fauret, A.-L.; Mirault, T.; Denarié, N.; Mousseaux, E.; et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers–Danlos syndrome. Eur. J. Hum. Genet. 2015, 23, 1657–1664.
  34. Bergqvist, D.; Björck, M.; Wanhainen, A. Treatment of Vascular Ehlers-Danlos Syndrome. Ann. Surg. 2013, 258, 257–261.
  35. Ong, K.-T.; Perdu, J.; De Backer, J.; Bozec, E.; Collignon, P.; Emmerich, J.; Fauret, A.-L.; Fiessinger, J.-N.; Germain, D.P.; Georgesco, G.; et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: A prospective randomised, open, blinded-endpoints trial. Lancet 2010, 376, 1476–1484.
  36. Dubacher, N.; Münger, J.; Gorosabel, M.C.; Crabb, J.; Ksiazek, A.A.; Caspar, S.M.; Bakker, E.N.T.P.; Van Bavel, E.; Ziegler, U.; Carrel, T.; et al. Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome. Cardiovasc. Res. 2020, 116, 457–465.
  37. Meester, J.A.N.; Vandeweyer, G.; Pintelon, I.; Lammens, M.; Van Hoorick, L.; De Belder, S.; Waitzman, K.; Young, L.; Markham, L.W.; Vogt, J.; et al. Loss-of-function mutations in the X-linked biglycan gene cause a severe syndromic form of thoracic aortic aneurysms and dissections. Genet. Med. 2017, 19, 386–395.
  38. Sheen, V.L.; Jansen, A.; Chen, M.H.; Parrini, E.; Morgan, T.; Ravenscroft, R.; Ganesh, V.; Underwood, T.; Wiley, J.; Leventer, R.; et al. Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology 2005, 64, 254–262.
  39. Chen, M.H.; Choudhury, S.; Hirata, M.; Khalsa, S.; Chang, B.; Walsh, C.A. Thoracic aortic aneurysm in patients with loss of function Filamin A mutations: Clinical characterization, genetics, and recommendations; Thoracic aortic aneurysm in patients with loss of function Filamin A mutations: Clinical characterization, genetics, and recommendations. Am. J. Med. Genet. A 2018, 176, 337–350.
  40. Guo, D.C.; Regalado, E.S.; Gong, L.; Duan, X.; Santos-Cortez, R.L.P.; Arnaud, P.; Ren, Z.; Cai, B.; Hostetler, E.M.; Moran, R.; et al. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ. Res. 2016, 118, 928–934.
  41. Wolford, B.N.; Hornsby, W.E.; Guo, D.; Zhou, W.; Lin, M.; Farhat, L.; McNamara, J.; Driscoll, A.; Wu, X.; Schmidt, E.M.; et al. Clinical Implications of Identifying Pathogenic Variants in Individuals With Thoracic Aortic Dissection. Circ. Genom. Precis. Med. 2019, 12, e002476.
  42. Coffey, S.; Cairns, B.J.; Iung, B. The modern epidemiology of heart valve disease. Heart 2016, 102, 75–85.
  43. Freeze, S.L.; Landis, B.J.; Ware, S.M.; Helm, B.M. Bicuspid Aortic Valve: A Review with Recommendations for Genetic Counseling. J. Genet. Couns. 2016, 25, 1171–1178.
  44. Galian-Gay, L.; Carro Hevia, A.; Teixido-Turà, G.; Rodríguez Palomares, J.; Gutiérrez-Moreno, L.; Maldonado, G.; Gonzàlez-Alujas, M.T.; Sao-Aviles, A.; Gallego, P.; Calvo-Iglesias, F.; et al. Familial clustering of bicuspid aortic valve and its relationship with aortic dilation in first-degree relatives. Heart 2019, 105, 603–608.
  45. Huntington, K.; Hunter, A.G.; Chan, K.L. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J. Am. Coll. Cardiol. 1997, 30, 1809–1812.
  46. Tadros, T.M.; Klein, M.D.; Shapira, O.M. Ascending Aortic Dilatation Associated With Bicuspid Aortic Valve. Circulation 2009, 119, 880–890.
  47. Davies, R.R.; Kaple, R.K.; Mandapati, D.; Gallo, A.; Botta, D.M.; Elefteriades, J.A.; Coady, M.A. Natural History of Ascending Aortic Aneurysms in the Setting of an Unreplaced Bicuspid Aortic Valve. Ann. Thorac. Surg. 2007, 83, 1338–1344.
  48. Prakash, S.K.; Bossé, Y.; Muehlschlegel, J.D.; Michelena, H.I.; Limongelli, G.; Della Corte, A.; Pluchinotta, F.R.; Russo, M.G.; Evangelista, A.; Benson, D.W.; et al. A roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: Insights from the International BAVCon (Bicuspid Aortic Valve Consortium). J. Am. Coll. Cardiol. 2014, 64, 832–839.
  49. Pileggi, S.; De Chiara, B.; Magnoli, M.; Franzosi, M.G.; Merlanti, B.; Bianchini, F.; Moreo, A.; Romeo, G.; Russo, C.F.; Rizzo, S.; et al. Sequencing of NOTCH1 gene in an Italian population with bicuspid aortic valve: Preliminary results from the GISSI OUTLIERS VAR study. Gene 2019, 715, 143970.
  50. Kent, K.C.; Crenshaw, M.L.; Goh, D.L.; Dietz, H.C. Genotype–phenotype correlation in patients with bicuspid aortic valve and aneurysm. J. Thorac. Cardiovasc. Surg. 2013, 146, 158–165.e1.
  51. Luyckx, I.; Maccarrick, G.; Kempers, M.; Meester, J.; Geryl, C.; Rombouts, O.; Peeters, N.; Claes, C.; Boeckx, N.; Sakalihasan, N.; et al. European Journal of Human Genetics Confirmation of the role of pathogenic SMAD6 variants in bicuspid aortic valve-related aortopathy. Eur. J. Hum. Genet. 2019, 5, 3552.
  52. Gillis, E.; Kumar, A.A.; Luyckx, I.; Preuss, C.; Cannaerts, E.; van de Beek, G.; Wieschendorf, B.; Alaerts, M.; Bolar, N.; Vandeweyer, G.; et al. Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor. Front. Physiol. 2017, 8, 400.
  53. Gould, R.A.; Aziz, H.; Woods, C.E.; Seman-Senderos, M.A.; Sparks, E.; Preuss, C.; Wünnemann, F.; Bedja, D.; Moats, C.R.; McClymont, S.A.; et al. ROBO4 variants predispose individuals to bicuspid aortic valve and thoracic aortic aneurysm. Nat. Genet. 2019, 51, 42–50.
  54. Luyckx, I.; Kumar, A.A.; Reyniers, E.; Dekeyser, E.; Vanderstraeten, K.; Vandeweyer, G.; Wünnemann, F.; Preuss, C.; Mazzella, J.-M.; Goudot, G.; et al. Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies TBX20 as a contributing gene. Eur. J. Hum. Genet. 2019, 27, 1033–1043.
  55. Coady, M.A.; Davies, R.R.; Roberts, M.; Goldstein, L.J.; Rogalski, M.J.; Rizzo, J.A.; Hammond, G.L.; Kopf, G.S.; Elefteriades, J.A. Familial Patterns of Thoracic Aortic Aneurysms. Arch. Surg. 1999, 134, 361.
  56. LeMaire, S.A.; McDonald, M.-L.N.; Guo, D.; Russell, L.; Miller, C.C.; Johnson, R.J.; Bekheirnia, M.R.; Franco, L.M.; Nguyen, M.; Pyeritz, R.E.; et al. Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat. Genet. 2011, 43, 996–1000.
  57. Weerakkody, R.; Ross, D.; Parry, D.A.; Ziganshin, B.; Vandrovcova, J.; Gampawar, P.; Abdullah, A.; Biggs, J.; Dumfarth, J.; Ibrahim, Y.; et al. Targeted genetic analysis in a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic aorta. Genet. Med. 2018, 20, 1414–1422.
  58. Morisaki, H.; Akutsu, K.; Ogino, H.; Kondo, N.; Yamanaka, I.; Tsutsumi, Y.; Yoshimuta, T.; Okajima, T.; Matsuda, H.; Minatoya, K.; et al. Human Mutation RESEARCH ARTICLE Mutation of ACTA2 Gene as an Important Cause of Familial and Nonfamilial Nonsyndromatic Thoracic Aortic Aneurysm and/or Dissection (TAAD). Hum. Mutat. 2009, 30, 1406–1411.
  59. Ke, T.; Han, M.; Zhao, M.; Wang, Q.K.; Zhang, H.; Zhao, Y.; Ruan, X.; Li, H.; Xu, C.; Sun, T. Alpha-actin-2 mutations in Chinese patients with a non-syndromatic thoracic aortic aneurysm. BMC Med. Genet. 2016, 17, 45.
  60. Van De Laar, I.M.B.H.; Arbustini, E.; Loeys, B.; Björck, E.; Murphy, L.; Groenink, M.; Kempers, M.; Timmermans, J.; Roos-Hesselink, J.; Benke, K.; et al. European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet J. Rare Dis. 2019, 14, 264.
  61. Hannuksela, M.; Stattin, E.-L.; Klar, J.; Ameur, A.; Johansson, B.; Sörensen, K.; Carlberg, B. A novel variant in MYLK causes thoracic aortic dissections: Genotypic and phenotypic description. BMC Med. Genet. 2016, 17, 61.
  62. Wang, L.; Guo, D.-C.; Cao, J.; Gong, L.; Kamm, K.E.; Regalado, E.; Li, L.; Shete, S.; He, W.-Q.; Zhu, M.-S.; et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am. J. Hum. Genet. 2010, 87, 701–707.
  63. Wallace, S.E.; Regalado, E.S.; Gong, L.; Janda, A.L.; Guo, D.-C.; Russo, C.F.; Kulmacz, R.J.; Hanna, N.; Jondeau, G.; Boileau, C.; et al. MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants. Genet. Med. 2019, 21, 144–151.
  64. Zhu, L.; Vranckx, R.; Van Kien, P.K.; Lalande, A.; Boisset, N.; Mathieu, F.; Wegman, M.; Glancy, L.; Gasc, J.-M.; Brunotte, F.; et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat. Genet. 2006, 38, 343–349.
  65. Ziganshin, B.A.; Bailey, A.E.; Coons, C.; Dykas, D.; Charilaou, P.; Tanriverdi, L.H.; Liu, L.; Tranquilli, M.; Bale, A.E.; Elefteriades, J.A. Routine Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting. Ann. Thorac. Surg. 2015, 100, 1604–1611.
  66. Guo, D.-C.; Pannu, H.; Tran-Fadulu, V.; Papke, C.L.; Yu, R.K.; Avidan, N.; Bourgeois, S.; Estrera, A.L.; Safi, H.J.; Sparks, E.; et al. Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat. Genet. 2007, 39, 1488–1493.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback